Strona główna・Stock List・Astellas Pharma Inc

Astellas Pharma Inc

Closed

1,688 1.69

Buy Sell

Overview

Share price change

24h

Current

Min

1678

Max

1697

Key metrics
By Trading Economics
Income	-48B -33B
Sales	-49B 373B
P/E Sector Avg	620.75
EPS	4.33
Profit margin	-8.916
EBITDA	-62B 4.2B

Dividends
By Dow Jones
Next Earnings	1 sie 2024
Next Ex Dividend date	26 wrz 2024

Market Stats
By TradingEconomics
Market Cap	120B 3T
Previous open	1686.31
Previous close	1688

Astellas Pharma Inc Chart

Related News

1 maj 2024, 16:54 UTC

Major Market Movers

Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences

7 sie 2023, 14:26 UTC

Major Market Movers

Poseida Therapeutics Shares Leap on Astellas Investments

28 sie 2023, 05:18 UTC

Acquisitions, Mergers, Takeovers

Novartis: Mycamine Is Antifungal Treatment

28 sie 2023, 05:16 UTC

Acquisitions, Mergers, Takeovers

Novartis: Sandoz Completes Acquisition of Mycamine Brand From Astellas

Astellas Pharma Inc Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About Astellas Pharma Inc

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.